Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11918770
Implants for localized drug delivery and methods of use thereof
granted -
US 11919880
HCV protease inhibitors
granted -
US 11918646
Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
granted -
US 11918620
Traditional Chinese medicine composition, and preparation method therefor and application thereof
granted -
US 11918686
Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
granted -
US 11912758
Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel
granted -
US 11911464
Anti-parasitic immunological compositions
granted -
US 11913883
Highly specific tissue imaging
granted -
US 11912986
Methods for screening genetic perturbations
granted -
US 11911367
Methods for treating cancer
granted -
US 11911376
Methods for preventing and treating retinal damage
granted -
US 11911482
Self assembling protein nanoparticles as carrier molecules
granted -
US 11912762
Method of treating osteoarthritis by administering an anti-connexin 43 antibody
granted -
US 11913027
Methods of treatment using pluripotent human adipose adult stem cells
granted -
US 11904054
Compositions and methods for delivering pharmaceutical agents
granted -
US 11904007
Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction
granted -
US 11903966
Intracellular genomic transplant and methods of therapy
granted -
US 11903936
Anti-malarial agents
granted -
US 11903952
Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection
granted -
US 11903970
Device and methods for platelet lysis or activation
granted -
US 11906519
Methods for identifying LILRB-blocking antibodies
granted -
US 11905297
OX2R compounds
granted -
US 11896417
Time-varying kinetic modeling of high temporal-resolution dynamic pet data for multiparametric imaging
granted -
US 11896724
Bioactive polymeric dressing for accelerated wound closure
granted -
US 11896558
Use of an RXR agonist and taxanes in treating Her2+ cancers
granted -
US 11896626
Multistrain population control systems and methods
granted -
US 11897969
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
granted -
US 11896658
RSV vaccines and methods of production and use thereof
granted -
US 11897932
Receptors for ligand-dependent transcriptional regulation
granted -
US 11896603
Oligosaccharide as therapeutic agent for alcohol associated liver disease
granted -
US 11891402
Compositions and methods for treating cancer
granted -
US 11890344
One-step processing of hydrogels for mechanically robust and chemically desired features
granted -
US 11891616
Transgene cassettes designed to express a human MECP2 gene
granted -
US 11892452
Disease-associated antigens and methods of use thereof
granted -
US 11890320
CLEC11A is a bone growth agent
granted -
US 11891426
CD19 variants
granted -
US 11883528
Compositions and methods for treating pulmonary edema or lung inflammation
granted -
US 11883423
Nucleobase analogue derivatives and their applications
granted -
US 11883441
Compositions and methods for inhibiting seizures
granted -
US 11884657
PI-kinase inhibitors with anti-infective activity
granted -
US 11884925
Synthetic immunomodulation with a CRISPR super-repressor in vivo
granted -
US 11884932
In vitro production of medial ganglionic eminence precursor cells
granted -
US 11883223
Hepatic inflammation analysis with dynamic PET
granted -
US 11884647
Compounds and methods for targeting pathogenic blood vessels
granted -
US 11883381
ASH1L inhibitors and methods of treatment therewith
granted -
US 11883492
Combination treatment of chemoresistant cancers
granted -
US 11885861
3-dimensional representations of post-contrast enhanced brain lesions
granted -
US 11884710
Peptide compounds and methods of use in wound healing
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory